Due to the rise in cases of Diabetic Neuropathy, it is predicted that the market for treating neuropathy pain would grow. A notable example of the condition's expanding prevalence is the International Diabetes Federation's 2016 study, which estimated that 420 million individuals worldwide had diabetes and that number will increase by 8.4% to 625 million by 2040. As a result, it is projected that risk factors for developing diabetes, such as smoking, being overweight or obese, and having high cholesterol levels, would grow. This will lead to an increase in the Neuropathic Pain Market. Consequently, the increase in diabetic cases has boosted the CAGR of the global neuropathic pain market in recent years.
The Neuropathic Pain Market has been segmented based on physical examination, blood tests, and imaging tests for diagnosis. The imaging industry dominated the market in 2021. The growing healthcare sector in emerging economies, as well as the demand for non-invasive and minimally invasive technology, are all expected to contribute to a growth in these areas. However due to increased R&D spending and regulatory bodies licencing neurorehabilitation devices as products, the physical examination market saw tremendous growth.
